Table 1.
The role of the β2 integrins in experimental BP
| IgG-injected | Treatment | No. mice | Mean disease activity* |
|---|---|---|---|
| Wild-type | |||
| R50 | – | 8 | 0.00 ± 0.00 |
| R530 | – | 22 | 2.59 ± 0.10 |
| R530 | Anti-CD11a | 12 | 0.08 ± 0.06 |
| R530 | Anti-CD11b | 8 | 0.25 ± 0.09 |
| R530 | Anti-CD11a + CD11b | 8 | 0.06 ± 0.06 |
| R530 | Anti-CD18 | 8 | 0.12 ± 0.08 |
| Mac-1 KO | |||
| R50 | – | 8 | 0.00 ± 0.00 |
| R530 | – | 16 | 0.00 ± 0.00 |
| R530 | 5 × 105 WT PMNs | 6 | 3.00 ± 0.00 |
| R530 | 5 × 105 Mac-1 KO PMNs | 6 | 3.00 ± 0.00 |
Neonatal WT and Mac-1-deficient (Mac-1 KO) mice were pretreated with isotype control IgG, anti-CD11a, anti-CD11b, anti-CD11a plus anti-CD11b, or anti-CD18. Two hours later, the mice were injected intradermally with either control rabbit IgG R50 or pathogenic rabbit anti-mBP180 IgG R530. For PMN reconstitution, Mac-1 KO mice were injected intradermally with R530 and 2 hours later locally reconstituted with 5 × 105 PMNs from Wt or Mac-1 KO mice. The animals were examined 24 hours after the pathogenic IgG injection.
The extent of cutaneous disease was scored as follows:–indicates no detectable skin disease; 1+, mild erythematous reaction with no evidence of the “epidermal detachment sign” `this sign was elicited by gentle friction of the mouse skin which, when positive, produced fine, persistent wrinkling of the epidermis'; 2+, intense erythema and epidermal detachment sign involving 10% to 50% of the epidermis in localized areas; and 3+, intense erythema with frank epidermal detachment sign involving more than 50% of the epidermis in the injection site. The clinical disease severity is expressed as mean ± SE and analyzed by paired Student t test. P < .001 (WT injected with R530 vs WT injected with R530 plus neutralizing antibody). Three to 4 independent experiments were done for each group of mice